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Abstract
There is a high need for novel treatment options in relapsed and refractory diffuse large B-cell lymphoma. Single agent mammalian 
target of rapamycin (mTOR) inhibitor treatment has shown promising efficacy in this entity. Here, we report on the results of the 
mTOR-inhibitor temsirolimus combined to standard rituximab-DHAP salvage regimen in a prospective, multicenter, phase II, open-la-
bel study. The STORM regimen consisted of rituximab 375 mg/m2 (day 2) and DHAP (dexamethasone 40 mg day 3-6, cisplatinum 
100 mg/m2 day 3, cytarabine 2 × 2  g/m2 day 4) with temsirolimus added on day 1 and 8 of a 21-day cycle, with 2 to 4 cycles 
planned. In part I, dose levels of 25, 50, 75, and 100 mg for temsirolimus were predefined. Based on the observed toxicity profile, 
a temsirolimus dose of 25 mg was defined as recommended dose for the part II extension cohort of the trial. The intention-to-treat 
cohort comprised 53 patients. Median age was 63 years and median number of prior regimen was 1. All but 1 patient had prior 
rituximab exposure. Temsirolimus dose was 50 mg on day 1 and 8 in 6 patients from the part I of the trial and 25 mg in the remaining 
47 patients. In general, treatment was well tolerated with leucopenia and thrombocytopenia as most frequent severe adverse events. 
The overall response rate after the last cycle of temsirolimus R-DHAP was 66% with 24% complete responses. The ability to mobilize 
stem cells was not impaired by the treatment regimen. Twenty-eight patients received consolidation treatment with high-dose therapy 
(HDT) and stem cell transplantation. Median duration of response was not reached. The total 2-year progression-free survival (PFS) 
and overall survival (OS) were 53% and 59%. Patients who were consolidated with HDT achieved a 2-year PFS and a 2-year OS of 
77.8% and 82.1%, respectively. We conclude that temsirolimus can be safely added to rituximab and DHAP with promising activity.
Introduction
Diffuse large B-cell lymphoma (DLBCL) is the most com-
mon type of non-Hodgkin’s lymphoma in the Western hemi-
sphere.1,2 Despite improvement of first-line therapy with the 
advent of rituximab and risk adapted treatment strategies,3–5 
a large proportion of patients will ultimately succumb to 
relapsed and refractory (r/r) disease. The current standard 
treatment of r/r DLBCL primarily consists of a intensified 
salvage therapy preceding transplant strategies, with regimens 
like R-DHAP, R-ICE, or R-GDP widely accepted.6,7 However, 
these regimens frequently fail to induce sufficient responses to 
allow for consolidation treatments. Therefore, there is an ulti-
mate need for improved salvage treatment approaches for r/r 
DLBCL. The mammalian target of rapamycin (mTOR) kinase 
is a key component of the PI3K/Akt pathway and involved in 
the transduction of downstream signals. This results in activa-
tion of nuclear transcription factors in healthy and malignant 
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cells. In lymphoma, a variety of mechanisms have been identi-
fied, which disturb the normal function of mTOR, for example, 
loss of the negative regulator PTEN, overexpression of mTOR, 
or overexpression of target genes as c-MYC and cyclin D1.8,9 
Temsirolimus is a selective inhibitor of mTOR. Besides solid 
cancers temsirolimus was evaluated in a variety of lymphoma 
entities.10 In r/r DLBCL, the response rate was 28% as single 
agent,11 stimulating further development. As preclinical data 
have shown synergism between mTOR inhibitors and cyto-
toxic agents,12 we postulated that the combination of mTOR 
inhibition to chemotherapy results in improved efficacy with 
acceptable toxicity. Consequently, in this study, we combined 
temsirolimus to the standard regimen R-DHAP (rituximab, 
dexamethasone, cytarabinoside, cisplatinum) for the treatment 
of r/r DLBCL.13
Methods
Conduct of the trial
According to national regulations, the study was approved 
by the competent authority Federal Institute for Drugs and 
Medical Devices (BfArM) and received a favorable opinion in 
a harmonized approach of the appropriate Ethic’s Committees. 
It was conducted in accordance with the German Medicines Act 
and Good Clinical Practice guidelines. Patients were required 
to sign informed consent before any study-related procedures. 
Trial conduct was supported by the Interdisciplinary Center for 
Clinical Trials (IZKS) of the University Medical Center Mainz. 
The trial was registered on EudraCT (2011-001491-20) and 
ClinicalTrials.gov (NCT01653067).
Study design
This was a prospective multicenter, phase II, open-label study 
to evaluate a salvage regimen of the mTOR inhibitor temsiro-
limus (Torisel) added to the standard therapy of rituximab and 
DHAP. The STORM-trial consisted of 2 parts. In the part I (dose 
escalation of temsirolimus), the primary objective was to estab-
lish a maximum tolerated dose of temsirolimus in combination 
with rituximab and DHAP. In the part II (full target dose), the 
primary objective was to evaluate the overall response rate 
(ORR). It was planned that at least 40 patients were enrolled to 
demonstrate an ORR of 65% with a complete response (CR) of 
40%. The recruitment period lasted from April 2013 to August 
2016.
Main eligibility criteria
Adult patients (≥18 years) with r/r DLBCL were eligible after 
signing informed consent. Patients had to have a histologically 
proven diagnosis of DLBCL according to the World Health 
Organization (WHO) classification, refractory disease, relapse, 
or progression following at least 1 treatment but a maximum 
of 2 prior lines. Since at the time the study was planned cell of 
origin (COO) status was not mandatory based on the WHO 
classification COO analysis was not routinely performed. Prior 
treatment must have included at least 3 cycles of anthracy-
cline containing chemotherapy (eg, CHOP-like) including an 
anti-CD20 antibody. There had to be at least 1 measurable 
tumor mass (>1.5 cm × >1.0 cm).
Participants had to have an adequate bone marrow reserve 
(platelets of at least 75000/μL, absolute neutrophil count at least 
1500/μL, hemoglobin of at least 10 g/dL) as well as liver (alanine 
aminotransferase < 2.5 × upper limit of normal [ULN]; aspar-
tate aminotransferase < 2.5 × ULN, total bilirubin < 1.5 × ULN 
except chronic hepatic conditions leading to bilirubin increase 
but not interfering therapy, eg, Gilbert’s Syndrome) and renal 
function (calculated creatinine clearance >70 mL/min). Eastern 
Cooperative Oncology Group (ECOG) performance status had 
to be <3. If applicable, effective birth control was to be used.
Treatment regimen
In part I of the trial, patients were planned to receive 25, 50, 
75, or 100 mg of temsirolimus on day 1 and day 8 in combi-
nation with R-DHAP (rituximab 375 mg/m2 day 2, dexameth-
asone 40 mg day 3-6, cisplatinum 100 mg/m2 day 3, cytarabine 
2 × 2 g/m2 day 4, q 22 days) in sequential cohorts. Cisplatinum 
could be replaced in the consecutive cycles by carboplatinum 
AUC 5 if the patient experienced kidney toxicity in the previ-
ous cycle, that is, decrease of creatinine clearance to 60 mL/min 
or lower. Two cycles of temsirolimus and R-DHAP were sched-
uled before first restaging, if clinically indicated, for example, 
to deepen response, patients were allowed to receive 2 further 
cycles of the regimen. Stem cell mobilization and subsequent 
high-dose consolidation therapy (HDCT) and autologous stem 
cell transplantation could be performed based on investigators 
description. Toxicities were graded according to the National 
Cancer Institute Common Terminology Criteria for Adverse 
Events (NCI CTCAE) version 4.03. Dose-limiting toxicities 
were defined as any CTCAE grade V toxicity with an at least 
possible relationship to the trial treatment and any hemato-
logical toxicity not recovering to at least NCI CTCAE grade 
II after 28 days after start of the last STORM-cycle (except as 
a consequence of bone marrow insufficiency due to bone mar-
row infiltration). Granulocyte colony-stimulating factor use 
was allowed up to the investigator discretion. In addition, any 
nonhematological toxicity NCI CTCAE grade III/IV not recov-
ering to grade II within 14 days after initial occurrence and 
with an at least possible relationship to the trial treatment was 
considered as dose-limiting toxicity (DLT). Lymphopenia was 
not considered as DLT. For maximum tolerated dose determi-
nation, a 6 + 6 standardized design was chosen. It was planned 
to include 6 patients into each dose level. After inclusion of 
6 patients, each patient had to receive at least 1 complete 
cycle without DLT until the enrolment into the next cohort 
could be initiated. DLTs were discussed with the Data Safety 
Monitoring Board (DSMB) for further recommendations.
Evaluations
All primary and secondary analyses were performed for 
the intention to treat (ITT) population which comprised all 
patients who received at least 1 dose of study treatment. As 
at the time of study initiation, there was limited access to 
PET-scanning, response to treatment was defined accord-
ing to the International Response Criteria for Non-Hodgkin 
Lymphoma.14 Initial staging included computed tomographic 
scans of the neck, chest, abdomen, and pelvis and radiological 
evaluation of all the affected regions. Restaging was sched-
uled after 2 cycles and at the end of treatment after final dose. 
Additional CT was performed every 3 months in the first 
year, every 6 months in the second and third year, and every 
12 months after the third year of follow-up. Patients were 
followed up to 5 years after end of the last STORM cycle. 
Progression-free survival (PFS) was defined as time from treat-
ment start to date of relapse, disease progression or death, or 
was censored at the last tumor evaluation date in case of no 
event; overall survival (OS) was measured as time from first 
dose to date of death or was censored at the last follow-up. 
After progression or the initiation of a new therapy, patients 
were followed with respect to survival. Duration of response 
(DoR) was defined as time from initial response to progression 
of disease or was censored in case of death or at the last tumor 
evaluation date in case of no event.
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Statistical analysis
Primary objectives
In the phase I proportion of the trial occurrence of DLTs were 
monitored to determine the maximum tolerated dose of temsiro-
limus. In the phase II proportion of the trial, the primary analy-
sis comprised ORR after the last cycle of temsirolimus R-DHAP. 
Overall response was defined as complete response (CR or 
CRu [CR unconfirmed]) or partial response at the respective 
time point based on International Working Group (IWG) rec-
ommendations. For overall response assessments until the end 
of follow-up, the last observation carried forward method was 
applied in case of missing values at the respective time point. 
95% confidence intervals were given.
Secondary objectives
PFS, OS, and DoR at end of last follow-up were analyzed for 
the combined data of part I and part II of the trial. Results for 
time to event end points were calculated according to Kaplan-
Meier estimator. The number of successful transplantations 
after stem cell mobilization and subsequent HDCT was ana-
lyzed descriptively.
Safety analysis
Special attention in part I and part II of the study was brought 
to monitoring of adverse events. Adverse events were classified 
by system organ class (SOC) and preferred term according to 
MedDRA terminology. Further analyses of adverse events com-
prise duration, whether the AE was serious, intensity, relation-
ship to trial treatment, action taken, and clinical outcome. SAS 
Version 9.4 was used for all calculations.
Results
Patients
In total, 55 patients were assessed for eligibility. Fifty-three 
patients were enrolled, 15 patients in part I and 38 in part II of 
the study. Two patients were excluded from the study: 1 patient 
was identified as screening failure and another patient withdrew 
informed consent before start of treatment, respectively. Patient 
characteristics are shown in Table 1. In brief, the ITT popula-
tion comprised 53 patients. Thirty-three patients (62%) were 
male, median age of the study population was 63 years (Q1-Q3: 
54-67 years). Fifty patients had received 1 prior treatment reg-
imen. All but 1 patient was pretreated with rituximab. Median 
time to relapse from initial lymphoma therapy to study enrol-
ment was 10 months and mean time was 24.2 months (range 
2-183 months). The last treatment of the last patient was in 
October 2016 and last follow-up took place in October 2018. 
Three patients were not available for efficacy analysis. Of these, 
2 patients withdrew consent prior and 1 patient died before first 
disease evaluation to restaging. The CONSORT diagram of the 
trial is shown in Figure 1.
Completion of treatment and relative dose 
intensity
In part I of the study, 9 patients received a dose of 25 mg tem-
sirolimus and 6 patients received a dose of 50 mg temsirolimus 
on day 1 and day 8 in combination with R-DHAP per treatment 
administration. In part II of the study, 38 patients received the 
recommended phase II dose of 25 mg temsirolimus on day 1 
and day 8 as determined in part I of the study. Median treat-
ment duration measured from first day to last day of treatment 
was 51.6 days. Overall, 83% of patients completed at least 2 
treatment cycles (median number of completed cycles: 2, range: 
0-4 cycles; Table 1). Median time between cycle 1 and 2 was 16 
days, between cycle 2 and 3 as well as cycle 3 and 4 the median 
time was 20 days. Thirty-one patients received cisplatin only (9 
in part I and 22 in part II), 21 patients received both cisplatin 
and carboplatin (6 in part I and 15 in part II), and 1 patient 
received carboplatin only in part II. Dose adherence was high 
(Table 2).
Maximum tolerated dose
Two formal dose-limiting toxicities were observed; 1 
esophagus infection in the 50 mg cohort and 1 venous throm-
bosis in the 25 mg cohort. Additionally, in 3 of 6 patients of 
the 50 mg cohort, a NCI CTCAE grade IV thrombocytopenia 
occurred. In 2 of these patients, the NCI CTCAE grade IV 
thrombocytopenia resolved only after 43 days. After discus-
sion with the data safety monitoring board therefore the rec-
ommended dose of temsirolimus was determined as of 25 mg 
on day 1 and 8, which was then used for the phase II propor-




50 mg  
(N = 6)




Age (y), median (range) 68 (50–73) 61 (23–77) 63 (23–77)
Age >60 y, n (%) 5 (83) 24 (51) 29 (55)
Sex, n (%)    
 Male 3 (50) 30 (64) 33 (62)
 Female 3 (50) 17 (36) 20 (38)
Stage at inclusion (%)    
 I 0 (0) 2 (4) 2 (4)
 II 0 (0) 17 (36) 17 (32)
 III 5 (83) 9 (19) 14 (26)
 IV 1 (17) 19 (40) 20 (38)
ECOG performance status, n (%), missing: 2   
 0 5 (83) 27 (60) 32 (63)
 1 1 (17) 12 (27) 13 (25)
 2 0 (0) 6 (13) 6 (12)
IPI score, n (%), missing: 26    
 1 0 (0) 3 (14) 3 (11)
 2 1 (20) 5 (23) 6 (22)
 3 3 (60) 10 (45) 13 (48)
 4 1 (20) 3 (14) 4 (15)
 5 0 (0) 1 (5) 1 (4)
Baseline aaIPI-score, n (%), missing: 29    
 0 0 (0) 1 (4) 1 (4)
 1 0 (0) 9 (39) 9 (38)
 2 1 (100) 10 (43) 11 (46)
 3 0 (0) 3 (13) 3 (13)
Disease stage III/IV, n (%), missing: 19 6 (100) 28 (60) 34 (64)
Bulky disease (>7.5 cm), n (%) 0 (0) 16 (34) 16 (30)
Elevated LDH, missing: 20 0 (0) 17 (54) 17 (51)
Bone marrow involvement, missing: 9 0 (0) 5 (13%) 5 (11)
Number of prior regimens (median, range: 1; 1–2) (%)   
 1 5 (83) 45 (96) 50 (94)
 2 1 (17) 2 (4) 3 (6)
 ≥3 0 (0) 0 (0) 0 (0)
 Prior radiotherapy 0 (0) 13 (28) 13 (25)
 Prior rituximab 6 (100) 46 (98) 52 (98)
 Time interval since last treatment <1 y 4 (67) 32 (68) 36 (68)
Response to most recent prior therapy, missing: 2 (%)   
 Complete response 5 (83) 20 (44) 25 (49)
 Partial response 0 (0) 9 (20) 9 (18)
 Stable disease 0 (0) 3 (7) 3 (6)
 Disease progression 1 (17) 13 (29) 14 (27)
aaIPI-score = age-adjusted international prognostic index; ECOG = Eastern Cooperative Oncology 
Group; IPI = international prognostic index; LDH = lactate dehydrogenase.
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Number of successful stem cell mobilizations und 
transplantations
Stem cells mobilization was initiated in 40 patients (78%) of 
which 38 patients (95%) had a successful mobilization. Of the 
38 patients who successfully collected stem cells, 23 received 
an autologous stem cell transplantation (SCT). Furthermore, 
5 patients received an allogeneic SCT based on the investiga-
tor discretion. Of the patients who received a transplant, 14 
patients had an early relapse after the last lymphoma therapy.
Adverse events
Overall, treatment was well tolerated. A total of 1678 adverse 
events (AEs) were reported (32 per patient). Interestingly, a 
trend of a dose-dependent difference of AE-number was noted, 
as 253 AEs (15%, 42 per patient) occurred in the group of 
patients treated with 50 mg temsirolimus and 1425 AEs (85%, 
30 per patient) occurred in the group of patients treated with 
25 mg temsirolimus. Supplemental Digital Content 1, Table 
1S, http://links.lww.com/HS/A200 shows the summary of 
related AEs allocated to MedDRA SOCs and treatment group. 
Overall, 538 AEs (32%) were graded as severe (CTCAE grade 
>2). Again, there was a trend to higher rate of severe AE with 
higher doses of temsiroliums with 99 (18%, 17 per patient) of 
the 538 severe AEs occurring in the group of patients treated 
with 50 mg temsirolimus and 439 (82%, 9 per patient) in the 
group of patients treated with 25 mg temsirolimus. The most 
Figure 1. CONSORT chart.
Table 2.
Treatment
Number of Started Treatment 
Cycles
50 mg  
(N = 6) (%)
25 mg  
(N = 47) (%)
Total  
(N = 53) (%)
1 1 (17) 5 (11) 6 (11)
2 0 (0) 15 (32) 15 (28)
3 1 (17) 20 (43) 21 (40)
4 4 (67) 7 (15) 11 (21)
Applications in Relation to Total Number of Cycles Started = 143 (%)
Temirolimus 275/286 (96)   
Rituximab 143/143 (100)   
Cisplatinum/carboplatinum 143/143 (100)   
Cytarabine 142/143 (99)   
Dexamethasone 545/572 (95)   
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frequent severe AE (>10%) are shown in Table  3 and were 
leukopenia (75%), thrombocytopenia (83%), anemia (57%), 
hypokalemia (25%), 102 serious adverse events (SAEs) (6%, 
2 per patient) were reported. Sixty-five SAEs were judged as 
related to the study medication and were considered as serious 
adverse reactions (SARs). Nine (14%, 2 per patient) of SARs 
occurred in the group of patients treated with 50 mg temsiro-
limus and 56 (86%, 1 per patient) occurred in the group of 
patients treated with 25 mg temsirolimus. Three of these 65 
SARs were assessed as unexpected by the sponsor (SUSAR) 
and were therefore reported to the competent authority, eth-
ics committee, and all investigators. The most frequent SAEs 
(>5%) were febrile neutropenia (7 patients) and thrombocyto-
penia (5 patients).
Response
The ORR in the ITT population at the end of the salvage 
therapy with temsirolimus R-DHAP was 66% (33 patients) 
with a 95% confidence interval of 52.87%-79.13%. CR was 
achieved by 24% (12 patients), of which 1 patient had an 
unconfirmed CR. Three patients had no response assessment 
and were excluded from the primary analysis. At end of last 
follow-up (ie, the last tumor evaluation after end of the last 
STORM-cycle), the ORR was 72% (36 patients) with a 95% 
confidence interval of 59.55%-84.45% and the CR rate was 
42% (28.32-55.68). Patients who received a SCT achieved an 
ORR of 93% (26 of 28 patients) after transplantation while 
patients without SCT had an ORR of only 45%. CR rates 
were 61% (17 patients) in patients with SCT versus 18% (4 
patients) without HDCT. Patients with HDCT who received 
an autologous stem cell transplantation had an ORR of 91% 
(21 patients) and a CR rate of 65% (15 patients). Mean DoR 
was not reached.
Survival
Two-year PFS rate was 53.1% for the entire group. Rates dif-
fered significantly between patients with and patients without 
HDCT therapy, with 2-year PFS rates of 77.8% and 24.0%, 
respectively. When separated by autologous versus allogeneic 
stem cell transplantation, 2-year PFS was 95.5% versus 0%. 
For OS, the 2-year survival rate was 58.9% for the entire group. 
Separated by HDCT, a 2-year OS rate of 82.1% in the group 
with and an OS rate of 30.6% in the group without HDCT 
were observed. When separated by autologous versus alloge-
neic stem cell transplantation, 2-year OS was 95.7% versus 
20%. Patients with late relapse had a superior PFS compared to 
patients with early relapse. Efficacy data are shown in Table 4 
and in Figures 2–4 and Supplemental Digital Content, Table S1, 
http://links.lww.com/HS/A199.
Discussion
The current standard treatment of patients r/r DLBCL con-
sists of an intensified salvage immunochemotherapy and, in 
case of chemosensitive disease, consolidation high-dose therapy 
(HDT) with either autologous or, in selected cases, allogeneic 
transplantation.15 However, in the rituximab era, HDT and 
autologous transplantation have shown only limited benefit in 
r/r DLBCL and allogeneic transplantation is limited to a par-
ticular patient population. This is underlined by the results of 
the CORAL trial, which showed that patients with r/r DLBCL 
experiencing relapse after today’s standard rituximab contain-
ing primary treatment have an adverse prognosis with stan-
dard salvage strategies, especially if relapse occurs within the 
first year after therapy or if the disease is primarily refractory.6 
Therefore, there is an ultimate need for improved salvage treat-
ment approaches for r/r DLBCL.
As mTOR inhibitors have shown preliminary efficacy in this 
entity as single agent,11 in the STORM trial, we aimed to eval-
uate the addition of the mTOR inhibitor temsirolimus to the 
standard rituximab-DHAP regimen. In the dose escalation in 
part I of the trial, temsirolimus 50 mg on day 1 and 8 resulted in 
pronounced and prolonged thrombocytopenia interfering with 
treatment continuation. Therefore, temsirolimus at a dose of 
25 mg on day 1 and 8 was selected as recommended dose for the 
subsequent phase II part of the trial. Consequently, the observed 
toxicity of the combination of standard rituximab DHAP and 
temsirolimus 25 mg on day 1 and 8 was within expected limits 
Table 3.
Related Adverse Events With a Frequency >10% of Patients
System Organ Class Preferred Term N %
Blood and lymphatic system disorders Anemia 30 57
 Febrile neutropenia 7 13
 Leukopenia 40 75
 Lymphopenia 11 21
 Neutropenia 24 45
 Thrombocytopenia 44 83
Gastrointestinal disorders Constipation 9 17
 Diarrhea 18 34
 Nausea 30 57
 Vomiting 16 30
General disorders Asthenia 6 11
 Fatigue 22 42
 Mucosal inflammation 14 26
 Pyrexia 13 25
Investigations Alanine aminotransferase 
increased
6 11
 Blood cholesterol increased 7 13
 Weight decreased 10 19
Metabolism and nutrition disorders Decreased appetite 12 23
 Hypertriglyceridemia 6 11
 Hypokalemia 13 25
Nervous system disorders Dizziness 7 13
 Dysgeusia 9 17
 Headache 11 21
 Polyneuropathy 6 11




Response Rates, Progression-free, and Overall Survival
Overall Response
50 mg  
(N = 6) (%)
25 mg  
(N = 47) (%)
Total  
(N = 53)
At end of salvage therapy, missing = 3    
 CR 2 (40) 10 (22) 12 (24%)
 PR 2 (40) 19 (42) 21 (42%)
 CR + PR 4 (80) 29 (64) 33 (66%)
 SD 0 (0) 7 (16) 7 (14%)
 PD 1 (20) 9 (20) 10 (20%)
At end of follow-up missing = 3    
 CR 4 (80) 17 (38) 21 (42%)
 PR 0 (0) 15 (33) 15 (30%)
 CR + PR 4 (80) 32 (71) 36 (72%)
 SD 0 (0) 2 (4) 2 (4%)
 PD 1 (20) 11 (24) 12 (24%)
Progression-free survival at 24 mo   53%
Overall survival at 24 mo   59%
CR = complete response; PD = progressive disease; PR = partial response; SD = stable disease.
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during the trial with neutropenia and thrombocytopenia as 
most frequent SAEs.
After the last cycle of temsirolimus R-DHAP, we observed an 
ORR of 66% with 24% complete remissions. This is a remark-
able result, in particular in the light of rituximab-pretreated 
patient population. If PET-CT would have been used, in par-
ticular, CR rates might have been superior in contrast to con-
ventional CT scanning.16 Not surprisingly, response rates could 
be further improved after HDT and stem cell transplantation in 
eligible patients.
The observed response rate of 66% (24% CR) and a 2-year 
PFS of 51% in the STORM trial compares favorably to pre-
vious trials that have evaluated standard R-DHAP, R-ICE, 
R-GDP, or ofatumumab DHAP after prior rituximab exposure. 
In the CORAL trial, where R-DHAP or R-ICE were investi-
gated, patients with prior rituximab treatment achieved an 
ORR of 51% and a 3-year PFS of 21%.6 Crump et al7 com-
pared R-DHAP and R-GDP in r/r DLBCL and observed an ORR 
of 45.1% in the GDP group and 44.1% in the DHAP group 
and an event free 4-year survival of 26% in both groups. The 
Figure 2. Duration of response. Kaplan-Meier analysis of duration of response (A) in the ITT population (B) related to HDCT and subsequent stem cell trans-
plantation. Dotted lines represent 95% confidence intervals. HDCT = high-dose consolidation therapy; ITT = intention to treat.
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ORCHARD trial examined R-DHAP and ofatumumab DHAP 
in r/r DLBCL and found an ORR of 38% after ofatumumab 
DHAP and 42% after R-DHAP with a 2-year PFS of 24% and 
26% only, respectively. Of note, in the ORCHARD trial, only 
151 of 447 patients actually got to autologous SCT. Of these 
patients, 99 of 151 were PET−ve after salvage pre-ASCT, while 
the respective 2-year PFS rates in PET−ve and PET+ve patients 
were 73% and 32%.17
Recently the treatment options in r/r DLBCL have signifi-
cantly expanded with the introduction of antibody drug con-
jugates such as polatuzumab,18 bispecific antibodies,19,20 and in 
particular CAR T-cell treatment.21,22 However, definite proof of 
superiority still needs to be shown in confirmatory trials. Until 
the results of these trials are available, salvage immunochemo-
therapy and consolidation with HDT in chemosensitive eligible 
patients remains the international therapeutic standard in r/r 
DLBCL.15 Interestingly, in trials examining CAR T-cell treat-
ment in r/r DLBCL, it was observed that this treatment is par-
ticularly feasible with few cytokine release syndromes and little 
neurotoxicity in patients with a low tumor volume,21,22 under-
lining that there still is a need for effective salvage regimens even 
in the CAR T-cell era. In addition, beside direct inhibition of 
Figure 3. Progression free survival. Kaplan-Meier analysis of progression-free survival (A) in the ITT population (B) related to HDCT and subsequent stem 
cell transplantation. Dotted lines represent 95% confidence intervals. HDCT = high-dose consolidation therapy; ITT = intention to treat.
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mTOR by temsirolimus, upstream blockade of mTOR signaling 
with PI3 kinase inhibitors might further improve tumor control 
in DLBCL.23
Taken together, we conclude that temsirolimus can be 
safely added to Rituximab and DHAP with promising activity. 
However, there are several important limitations to our results. 
First, as PET was not performed in the majority of patients, we 
could not determine treatment response according to the revised 
IWG criteria,16 which today is the international gold standard. 
Second, COO and high-risk molecular characteristics (eg, dou-
ble hit, triple hit) were not assessed at the time of relapse, there-
fore we cannot address the respective subgroups in our analysis. 
Finally, our results are based on a limited number of patients 
but underline a potential role of mTOR inhibitors as additive 
to chemoimmunotherapy in aggressive lymphoma. Everolimus 
combined with R-CHOP results induced a high complete 
Figure 4. Overall survival. Kaplan-Meier analysis of overall survival (A) in the ITT population (B) related to HDCT and subsequent stem cell transplantation. 
Dotted lines represent 95% confidence intervals. HDCT = high-dose consolidation therapy; ITT = intention to treat.
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metabolic remission rate (96%) in a small phase-II trial of 24 
patients with DLBCL.24 While postinduction maintenance treat-
ment with everolimus after R-CHOP failed to improve the PFS 
in a randomized phase-III trial,25 this is more likely attributed 
to the questionable concept of maintenance in DLBCL as to 
the question if a synergism can be observed if mTOR inhibitors 
are combined with chemotherapy. In conclusion, the promising 
results of our trial merits further development in prospective 
comparisons for salvage therapies in r/r DLBCL.
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